CYP26A1 Genotype

Vitamin A does more than support vision. A specific form of it, called retinoic acid, acts like a chemical conductor that tells cells where to go, what to become, and when to stop dividing. The CYP26A1 (cytochrome P450 family 26 subfamily A member 1) gene encodes one of the main enzymes that clears retinoic acid from your tissues, keeping the signal at the right strength.

This is a one-time test that reports the version of CYP26A1 you inherited. The result will not change over your lifetime. It is an exploratory marker rather than a standardized clinical test, but for people thinking carefully about how their genes interact with diet and development, the genotype offers a window into a pathway that does not appear on any standard panel.

What This Gene Actually Does

CYP26A1 is part of a small family of three closely related enzymes (CYP26A1, CYP26B1, and CYP26C1) that share the job of breaking down retinoic acid, the active version of vitamin A. All three act on the main form, all-trans-retinoic acid, but they differ in how well they handle the other naturally occurring forms (9-cis and 13-cis retinoic acid). CYP26C1 has the broadest reach across these forms, while CYP26A1 and CYP26B1 work mostly on the all-trans form. Without these enzymes, retinoic acid would accumulate in tissues that need to keep it low.

The enzymes are not expressed everywhere at the same level. Each one turns on in specific tissues and cell types, and retinoic acid itself can trigger more of the enzyme to be made (a feedback loop). This pattern helps the body sculpt precise concentration gradients of retinoic acid, which is how cells in a developing embryo or in adult tissues know their location and identity.

Why Your Genotype Matters

Different versions of CYP26A1 can change how active the enzyme is. Some variants increase activity, which could lower local retinoic acid levels. Others reduce or eliminate function. This matters because retinoic acid signaling is sensitive to small shifts, and the amount of vitamin A coming in through diet adds another layer of variability.

Researchers have looked at CYP26A1 in people with neural tube defects such as spina bifida, since the developmental biology of the gene makes it a plausible candidate. Findings so far are limited to small case series and rare variants of uncertain significance, not population-level risk estimates. CYP26A1 is mentioned in this context because it sits inside a developmental pathway of interest, not because a clinical risk has been established.

Developmental and Tissue Patterning

In animal models, CYP26A1 is essential for normal hindbrain patterning, vertebral identity, and the formation of structures at the lower end of the body. When the enzyme is missing or reduced, the resulting failure to clear retinoic acid produces caudal defects. This biology is why CYP26A1 has drawn attention in research on congenital malformations.

In a small human cohort of 21 patients with persistent cloaca (a rare malformation of the lower urinary, reproductive, and digestive tracts), about 23 percent carried damaging mutations in genes that regulate retinoic acid metabolism, including a transcription factor called CDX2 that directly controls CYP26A1 expression. Cell experiments showed that CDX2 mutations altered CYP26A1 levels, and the broader literature suggests that loss of CDX2 function tends to prolong retinoic acid signaling. The takeaway is that both too much and too little retinoic acid activity can disturb development.

What the Related Enzyme Tells Us

Most of the human disease data on this enzyme family come from CYP26B1, a close relative of CYP26A1 that does similar work. Whether the same patterns apply to CYP26A1 specifically has not been confirmed. Still, the CYP26B1 findings are worth knowing because they show the kinds of conditions where retinoic acid metabolism appears to matter.

A common CYP26B1 variant that increases enzyme activity has been associated with about 1.28 times the odds of esophageal squamous cell carcinoma, and people carrying it had lower blood levels of all-trans-retinoic acid. The same variant was linked to slightly larger atherosclerotic plaques and higher CYP26B1 expression inside those plaques, hinting that retinoic acid may have a protective vascular role. The variant has also been proposed, at borderline statistical significance, to influence Crohn disease. These are CYP26B1 findings, not CYP26A1 findings, but they describe the disease space the broader enzyme family touches.

Why One-Time Testing Makes Sense Here

Because CYP26A1 is a fixed inherited sequence, you only need to test it once. The genotype you have today is the genotype you will have at 80. What changes over time is your context: your diet, your supplement choices, your stage of life. A baseline genotype gives you a stable reference point to interpret those changes against.

If you are planning a pregnancy, recovering from one, or thinking about high-dose vitamin A or retinoid supplementation, knowing your CYP26A1 status is more useful than retesting it. The same applies if you have a family history of neural tube defects or other caudal malformations and want to understand whether retinoic acid metabolism is part of the inherited picture.

When Results Can Be Misleading

Genetic tests carry their own set of confounders that differ from blood-based labs. The most important ones for a CYP26A1 result are:

• Variant panel coverage: the test only reads the specific variants it is designed to detect. A negative result means none of those specific variants were found. It does not rule out rarer mutations elsewhere in the gene.
• Ancestry effects: some variants are common in one population and almost absent in another. The clinical meaning of a result can depend on the ancestry the variant was originally studied in.
• Variants of uncertain significance: an unexpected change may be reported with no clear interpretation. Most rare CYP26A1 variants fall into this category because the gene has been studied in only a small number of people.
• Direct-to-consumer versus clinical assays: a result from a recreational genotyping service is not equivalent to a clinical-grade test for the same locus, and confirmatory testing may be needed before acting on a finding.

Decision Pathway for an Unexpected Result

Because CYP26A1 is a research-grade marker without standardized clinical cutpoints, a notable result should prompt a workup rather than an immediate action. The pathway depends on the context that brought you to the test.

If you received an unexpected variant call, consider confirmatory testing by a different method (such as Sanger sequencing after a SNP chip result) before drawing conclusions. A consultation with a genetic counselor is reasonable, particularly if you are planning a pregnancy or have a family history of neural tube defects, persistent cloaca, or related caudal malformations. Biological family members may want to know the result, since they share part of your genome and any inherited variant has implications for them as well.

Carrying a variant in a developmental pathway does not mean you or your children will experience a related condition. Most people with sequence changes in genes like CYP26A1 develop normally, because human biology has many redundant systems. The genotype is one input among many.